Further, cell viability following treatments of oxaliplatin monotherapy and the combination of oxaliplatin and ATR inhibitor was assayed to explore the therapeutic potential of drug combination of ATR inhibitor and oxaliplatin in GC cells, especially in the PAK6 overexpressing cells. Here, PAK6 is linked to gastric cancer.